Standard of Care sensibility: Anti-PD1 = no / Anti PDL1 = yes (12,5 mg/kg)
Acquired resistance to: PDL1
MBT-2 cells
Mouse MBT-2 cells are derived from C3H/He bladder transitional cells serially transplanted and exposed to FANFT
Tumour growth in vivo
The cells were collected from a tissue culture flask and injected subcutaneously in the right flank of C3H/He mice. The resulting tumours were monitored by measuring two diameters with calipers, and extrapolating the volume to a sphere.
The mice bearing MBT-2 tumours can be treated by intra-peritoneal, intra-venous, intra-tumoral or subcutaneous injection of the compounds. Per os administration is also possible.
Figure 1: (View PDF)
Tumour growth curve of the MBT-2 cells as subcutaneous tumours Mean ± SEM (n=4; take rate 100%)
Drug Responses
Anti-PD1 12.5 mg/kg → No reponse
Anti-PDL1 12.5 mg/kg → Response
Immunophenotyping data of the lymphoid and myeloid lineage are available upon request.
Antineo has developed models of secondary resistance to anti-PDL1 (ID MBT-2 anti-PDL1R). These models have been developed in vivo without genetic modifications.